View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Gyermekgyógyászati Klinika Budapest Tűzoltó u. 7–9. 1094
  • 2 Debreceni Egyetem, Általános Orvostudományi Kar Infektológiai és Gyermekimmunológiai Tanszék Debrecen
  • 3 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest
  • 4 Gottsegen György Országos Kardiológiai Intézet Budapest
  • 5 Semmelweis Egyetem, Általános Orvostudományi Kar Neurológiai Klinika Budapest
  • 6 Semmelweis Egyetem, Általános Orvostudományi Kar Pulmonológiai Klinika Budapest
  • 7 Semmelweis Egyetem, Általános Orvostudományi Kar Bőrgyógyászati Klinika Budapest
  • 8 Semmelweis Egyetem, Általános Orvostudományi Kar Szemészeti Klinika Budapest
  • 9 Semmelweis Egyetem Tudásközpont, MR-labor Budapest
  • 10 Debreceni Egyetem, Általános Orvostudományi Kar Kardiológiai Klinika Debrecen
  • 11 Debreceni Egyetem, Általános Orvostudományi Kar Neurológiai Klinika Debrecen
Open access

A Fabry-kór a lizoszomális tárolási betegségek csoportjába tartozó, X-kromoszómához kötötten, recesszív módon öröklődő betegség, amely a globotriaozilceramid felhalmozódásához vezet a szervezet legkülönbözőbb szöveteiben. A betegség első tünetei többnyire gyermekkorban jelentkeznek, a progresszió során a betegek súlyos szervi károsodásokkal és korai halálozással számolhatnak. Elsősorban férfiak érintettek, azonban a betegség tüneteit heterozigóta nők esetében is megfigyelhetjük, de náluk a kórkép súlyossága változó, általában enyhébb lefolyású. Az enzimpótló kezelések megjelenése szükségessé tette, hogy részletes diagnosztikus és terápiás protokollt dolgozzunk ki. A jelen dolgozatban megjelenő ajánlásokat egy, a magyarországi Fabry-kóros betegek kezelésében részt vevő orvosokból, a diagnosztika területén dolgozó biológosukból és egyéb szakemberekből álló multidiszciplináris munkacsoport foglalta össze. A munkacsoport áttekintette a korábbi klinikai tanulmányokat, a publikált vizsgálatokat és a közelmúltban megjelent nemzetközi és nemzeti útmutatókat.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Constantin T., Rákóczi E., Ponyi A. és mtsai: Fabry–betegség – Diagnosztikai útmutató. Orv. Hetil., 2010, 151 , 243–249.

    Ponyi A. , 'Fabry–betegség – Diagnosztikai útmutató ' (2010 ) 151 Orv. Hetil. : 243 -249.

    • Search Google Scholar
  • Eng, C. M., Germain, D. P., Banikazemi, M. és mtsai: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med., 2006, 8 , 539–548.

    Banikazemi M. , 'Fabry disease: guidelines for the evaluation and management of multi-organ system involvement ' (2006 ) 8 Genet. Med. : 539 -548.

    • Search Google Scholar
  • Schaefer, R. M., Tylki-Szymanska, A., Hilz M. J.: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs, 2009, 69 , 2179–2205.

    Hilz M. J. , 'Enzyme replacement therapy for Fabry disease: a systematic review of available evidence ' (2009 ) 69 Drugs : 2179 -2205.

    • Search Google Scholar
  • Connock, M., Juarez-Garcia, A., Frew, E. és mtsai: A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol. Assess., 2006, 10 , 113.

    Frew E. , 'A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1 ' (2006 ) 10 Health Technol. Assess. : 113 -.

    • Search Google Scholar
  • Desnick, R. J., Banikazemi M.: Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol. Ther., 2006, 2 , S172–S185.

    Banikazemi M. , 'Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy ' (2006 ) 2 Nephrol. Ther. : S172 -S185.

    • Search Google Scholar
  • Clarke, L. A., Clarke, J. T., Sirrs, S. és mtsai: Fabry disease: Recommendations for diagnosis, management, and enzyme replacement therapy in Canada. 2005.

  • Hughes, D. A., Elliott, P. M., Lee, D. P. és mtsai: Guidelines for the diagnosis and management of Anderson-Fabry disease. London, 2003.

  • Desnick, R. J.: Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert. Opin. Biol. Ther., 2004, 4 , 1167–1176.

    Desnick R. J. , 'Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval ' (2004 ) 4 Expert. Opin. Biol. Ther. : 1167 -1176.

    • Search Google Scholar
  • EMEA. http://www.emea.eu.int/humandocs/Humans/EPAR/replagal/replagal.htm , 2001

  • Schiffmann, R., Kopp, J. B., Austin, H. A. 3rd és mtsai: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA, 2001, 285 , 2743–2749.

    Austin H. A. , 'Enzyme replacement therapy in Fabry disease: a randomized controlled trial ' (2001 ) 285 JAMA : 2743 -2749.

    • Search Google Scholar
  • Eng, C. M., Guffon, N., Wilcox, W. R. és mtsai: Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N. Engl. J. Med., 2001, 345 , 9–16.

    Wilcox W. R. , 'Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease ' (2001 ) 345 N. Engl. J. Med. : 9 -16.

    • Search Google Scholar
  • Eng, C. M., Banikazemi, M., Gordon, R. E. és mtsai: A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet., 2001, 68 , 711–722.

    Gordon R. E. , 'A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies ' (2001 ) 68 Am. J. Hum. Genet. : 711 -722.

    • Search Google Scholar
  • Wilcox, W. R., Banikazemi, M., Guffon, N. és mtsai: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet., 2004, 75 , 65–74.

    Guffon N. , 'Long-term safety and efficacy of enzyme replacement therapy for Fabry disease ' (2004 ) 75 Am. J. Hum. Genet. : 65 -74.

    • Search Google Scholar
  • Hoffmann, B., Garcia de Lorenzo, A., Mehta, A. és mtsai: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J. Med. Genet., 2005, 42 , 247–252.

    Mehta A. , 'Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey) ' (2005 ) 42 J. Med. Genet. : 247 -252.

    • Search Google Scholar
  • Schiffmann, R., Floeter, M. K., Dambrosia, J. M. és mtsai: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve, 2003, 28 , 703–710.

    Dambrosia J. M. , 'Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease ' (2003 ) 28 Muscle Nerve : 703 -710.

    • Search Google Scholar
  • Weidemann, F., Breunig, F., Beer, M. és mtsai: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation, 2003, 108 , 1299–1301.

    Beer M. , 'Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study ' (2003 ) 108 Circulation : 1299 -1301.

    • Search Google Scholar
  • Spinelli, L., Pisani, A., Sabbatini, M. és mtsai: Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin. Genet., 2004, 66 , 158–165.

    Sabbatini M. , 'Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease ' (2004 ) 66 Clin. Genet. : 158 -165.

    • Search Google Scholar
  • Schiffmann, R., Ries, M., Timmons, M. és mtsai: Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant., 2006, 21 , 345–354.

    Timmons M. , 'Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting ' (2006 ) 21 Nephrol. Dial. Transplant. : 345 -354.

    • Search Google Scholar
  • Breunig, F., Weidemann, F., Strotmann, J. és mtsai: Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int., 2006, 69 , 1216–1221.

    Strotmann J. , 'Clinical benefit of enzyme replacement therapy in Fabry disease ' (2006 ) 69 Kidney Int. : 1216 -1221.

    • Search Google Scholar
  • Breunig, F., Wanner, C.: Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J. Nephrol., 2008, 21 , 32–37.

    Wanner C. , 'Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy ' (2008 ) 21 J. Nephrol. : 32 -37.

    • Search Google Scholar
  • Banikazemi, M., Bultas, J., Waldek, S. és mtsai: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med., 2007, 146 , 77–86.

    Waldek S. , 'Agalsidase-beta therapy for advanced Fabry disease: a randomized trial ' (2007 ) 146 Ann. Intern. Med. : 77 -86.

    • Search Google Scholar
  • Lidove, O., Joly, D., Barbey, F. és mtsai: Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int. J. Clin. Pract., 2007, 61 , 293–302.

    Barbey F. , 'Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature ' (2007 ) 61 Int. J. Clin. Pract. : 293 -302.

    • Search Google Scholar
  • Wanner, C.: Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies. Int. J. Clin. Pract., 2007, 61 , 1234–1235., author reply 5.

    Wanner C. , 'Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies ' (2007 ) 61 Int. J. Clin. Pract. : 1234 -1235., author reply 5.

    • Search Google Scholar
  • Cho, M. E., Kopp, J. B.: Treatment of Fabry disease. In: Rose, B. D., Rush, J. M. (eds): UpToDate online. [Wellesley, Mass.] UpToDate, 2007.

  • Vedder, A. C., Linthorst, G. E., Houge, G. és mtsai: Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE, 2007, 2 , e598.

    Houge G. , 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg ' (2007 ) 2 PLoS ONE : e598 -.

    • Search Google Scholar
  • Vedder, A. C., Breunig, F., Donker-Koopman, W. E. és mtsai: Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol. Genet. Metab., 2008, 94 , 319–325.

    Donker-Koopman W. E. , 'Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3 ' (2008 ) 94 Mol. Genet. Metab. : 319 -325.

    • Search Google Scholar
  • Chimenti, C., Pieroni, M., Morgante, E. és mtsai: Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 2004, 110 , 1047–1053.

    Morgante E. , 'Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy ' (2004 ) 110 Circulation : 1047 -1053.

    • Search Google Scholar
  • Conti, G., Sergi, B.: Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr., 2003, 92 , 33–37., discussion 27.

    Sergi B. , 'Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females ' (2003 ) 92 Acta Paediatr. : 33 -37., discussion 27.

    • Search Google Scholar
  • Deegan, P. B., Baehner, A. F., Barba Romero, M. A. és mtsai: Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet., 2006, 43 , 347–352.

    Barba Romero M. A. , 'Natural history of Fabry disease in females in the Fabry Outcome Survey ' (2006 ) 43 J. Med. Genet. : 347 -352.

    • Search Google Scholar
  • Eng, C. M., Fletcher, J., Wilcox, W. R. és mtsai: Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis., 2007, 30 , 184–192.

    Wilcox W. R. , 'Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry ' (2007 ) 30 J. Inherit. Metab. Dis. : 184 -192.

    • Search Google Scholar
  • Fellgiebel, A., Muller, M. J., Mazanek, M. és mtsai: White matter lesion severity in male and female patients with Fabry disease. Neurology, 2005, 65 , 600–602.

    Mazanek M. , 'White matter lesion severity in male and female patients with Fabry disease ' (2005 ) 65 Neurology : 600 -602.

    • Search Google Scholar
  • Ortiz, A., Oliveira, J. P., Waldek, S. és mtsai: Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant., 2008, 23 , 1600–1607.

    Waldek S. , 'Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy ' (2008 ) 23 Nephrol. Dial. Transplant. : 1600 -1607.

    • Search Google Scholar
  • Wang, R. Y., Lelis, A., Mirocha, J. és mtsa: Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med., 2007, 9 , 34–45.

    Mirocha J. , 'Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life ' (2007 ) 9 Genet. Med. : 34 -45.

    • Search Google Scholar
  • Wilcox, W. R., Oliveira, J. P., Hopkin, R. J. és mtsai: Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol. Genet. Metab., 2008, 93 , 112–128.

    Hopkin R. J. , 'Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry ' (2008 ) 93 Mol. Genet. Metab. : 112 -128.

    • Search Google Scholar
  • Baehner, F., Kampmann, C., Whybra, C. és mtsai: Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J. Inherit. Metab. Dis., 2003, 26 , 617–627.

    Whybra C. , 'Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study ' (2003 ) 26 J. Inherit. Metab. Dis. : 617 -627.

    • Search Google Scholar
  • Elleder, M., Poupetova, H., Kozich, V.: Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I. Cesk. Patol., 1998, 34 , 7–12.

    Kozich V. , 'Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I ' (1998 ) 34 Cesk. Patol. : 7 -12.

    • Search Google Scholar
  • Mehta, A., Ricci, R., Widmer, U. és mtsai: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest., 2004, 34 , 236–242.

    Widmer U. , 'Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey ' (2004 ) 34 Eur. J. Clin. Invest. : 236 -242.

    • Search Google Scholar
  • Desnick, R. J., Brady, R. O.: Fabry disease in childhood. J. Pediatr., 2004, 144 , S20–S26.

    Brady R. O. , 'Fabry disease in childhood ' (2004 ) 144 J. Pediatr. : S20 -S26.

  • Ramaswami, U., Whybra, C., Parini, R. és mtsai: Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr., 2006, 95 , 86–92.

    Parini R. , 'Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey ' (2006 ) 95 Acta Paediatr. : 86 -92.

    • Search Google Scholar
  • Shah, J. S., Elliott, P. M.: Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr., 2005, 94 , 11–14; discussion 9–10.

    Elliott P. M. , 'Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy ' (2005 ) 94 Acta Paediatr. : 11 -14; discussion 9–10.

    • Search Google Scholar
  • Hughes, D. A., Elliott, P. M., Shah, J. és mtsai: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart, 2008, 94 , 153–158.

    Shah J. , 'Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa ' (2008 ) 94 Heart : 153 -158.

    • Search Google Scholar
  • Hoffmann, B., Beck, M., Sunder-Plassmann, G. és mtsai: Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey. Clin. J. Pain, 2007, 23 , 535–542.

    Sunder-Plassmann G. , 'Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey ' (2007 ) 23 Clin. J. Pain : 535 -542.

    • Search Google Scholar
  • Bierer, G., Balfe, D., Wilcox, W. R. és mtsa: Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis., 2006, 29 , 572–579.

    Wilcox W. R. , 'Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease ' (2006 ) 29 J. Inherit. Metab. Dis. : 572 -579.

    • Search Google Scholar
  • Ramaswami, U., Wendt, S., Pintos-Morell, G. és mtsai: Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr., 2007, 96 , 122–127.

    Pintos-Morell G. , 'Enzyme replacement therapy with agalsidase alfa in children with Fabry disease ' (2007 ) 96 Acta Paediatr. : 122 -127.

    • Search Google Scholar
  • Ries, M., Clarke, J. T., Whybra, C. és mtsai: Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics, 2006, 118 , 924–932.

    Whybra C. , 'Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease ' (2006 ) 118 Pediatrics : 924 -932.

    • Search Google Scholar
  • Askari, H., Kaneski, C. R., Semino-Mora, C. és mtsai: Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch., 2007, 451 , 823–834.

    Semino-Mora C. , 'Cellular and tissue localization of globotriaosylceramide in Fabry disease ' (2007 ) 451 Virchows Arch. : 823 -834.

    • Search Google Scholar
  • Orteu, C. H., Jansen, T., Lidove, O. és mtsai: Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br. J. Dermatol., 2007, 157 , 331–337.

    Lidove O. , 'Fabry disease and the skin: data from FOS, the Fabry outcome survey ' (2007 ) 157 Br. J. Dermatol. : 331 -337.

    • Search Google Scholar
  • Sodi, A., Ioannidis, A. S., Mehta, A. és mtsai: Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br. J. Ophthalmol., 2007, 91 , 210–214.

    Mehta A. , 'Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey ' (2007 ) 91 Br. J. Ophthalmol. : 210 -214.

    • Search Google Scholar
  • Mastropasqua, L., Nubile, M., Lanzini, M. és mtsai: Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. Am. J. Ophthalmol., 2006, 141 , 709–718.

    Lanzini M. , 'Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study ' (2006 ) 141 Am. J. Ophthalmol. : 709 -718.

    • Search Google Scholar
  • Nguyen, T. T., Gin, T., Nicholls, K. és mtsai: Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin. Experiment. Ophthalmol., 2005, 33 , 164–168.

    Nicholls K. , 'Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre ' (2005 ) 33 Clin. Experiment. Ophthalmol. : 164 -168.

    • Search Google Scholar
  • Cho, M. E., Kopp, J. B.: Clinical features and dignosis of Fabry disease. In: Rose, B. D., Rush, J. M. (eds): UpToDate online. [Wellesley, Mass.] UpToDate, 2007.

  • Zhang, S. H., Liu, Z. H., Zeng, C. H. és mtsai: Fabry disease: renal biopsy-proven cases from China. J. Nephrol., 2007, 20 , 716–726.

    Zeng C. H. , 'Fabry disease: renal biopsy-proven cases from China ' (2007 ) 20 J. Nephrol. : 716 -726.

    • Search Google Scholar
  • Warnock, D. G.: Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr. Opin. Nephrol. Hypertens., 2005, 14 , 87–95.

    Warnock D. G. , 'Fabry disease: diagnosis and management, with emphasis on the renal manifestations ' (2005 ) 14 Curr. Opin. Nephrol. Hypertens. : 87 -95.

    • Search Google Scholar
  • Thurberg, B. L., Rennke, H., Colvin, R. B. és mtsai: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int., 2002, 62 , 1933–1946.

    Colvin R. B. , 'Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy ' (2002 ) 62 Kidney Int. : 1933 -1946.

    • Search Google Scholar
  • Breunig, F., Weidemann, F., Beer, M. és mtsai: Fabry disease: diagnosis and treatment. Kidney Int., 2003, 63 , S181–S185.

    Beer M. , 'Fabry disease: diagnosis and treatment ' (2003 ) 63 Kidney Int. : S181 -S185.

  • Warnock, D. G., West, M. L.: Diagnosis and management of kidney involvement in Fabry disease. Adv. Chronic. Kidney Dis., 2006, 13 , 138–147.

    West M. L. , 'Diagnosis and management of kidney involvement in Fabry disease ' (2006 ) 13 Adv. Chronic. Kidney Dis. : 138 -147.

    • Search Google Scholar
  • Warnock, D. G.: Enzyme replacement therapy and Fabry kidney disease: quo vadis? J. Am. Soc. Nephrol., 2007, 18 , 1368–1370.

    Warnock D. G. , 'Enzyme replacement therapy and Fabry kidney disease: quo vadis? ' (2007 ) 18 J. Am. Soc. Nephrol. : 1368 -1370.

    • Search Google Scholar
  • Tahir, H., Jackson, L. L., Warnock, D. G. és mtsai: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J. Am. Soc. Nephrol., 2007, 18 , 2609–2617.

    Warnock D. G. , 'Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta ' (2007 ) 18 J. Am. Soc. Nephrol. : 2609 -2617.

    • Search Google Scholar
  • Wanner, C., Breunig, F.: Fabry nephropathy and the case for adjunctive renal therapy. J. Am. Soc. Nephrol., 2007, 18 , 2426–2428.

    Breunig F. , 'Fabry nephropathy and the case for adjunctive renal therapy ' (2007 ) 18 J. Am. Soc. Nephrol. : 2426 -2428.

    • Search Google Scholar
  • Branton, M. H., Schiffmann, R., Sabnis, S. G. és mtsai: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine, 2002, 81 , 122–138.

    Sabnis S. G. , 'Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course ' (2002 ) 81 Medicine : 122 -138.

    • Search Google Scholar
  • Kleinert, J., Dehout, F., Schwarting, A. és mtsai: Prevalence of uncontrolled hypertension in patients with Fabry disease. Am. J. Hypertens., 2006, 19 , 782–787.

    Schwarting A. , 'Prevalence of uncontrolled hypertension in patients with Fabry disease ' (2006 ) 19 Am. J. Hypertens. : 782 -787.

    • Search Google Scholar
  • Gantenbein, H., Bruder, E., Burger, H. R. és mtsai: Recurrence of Fabry’s disease in a renal allograft 14 years after transplantation. Nephrol. Dial. Transplant., 1995, 10 , 287–289.

    Burger H. R. , 'Recurrence of Fabry’s disease in a renal allograft 14 years after transplantation ' (1995 ) 10 Nephrol. Dial. Transplant. : 287 -289.

    • Search Google Scholar
  • Mignani, R., Feriozzi, S., Pisani, A. és mtsai: Agalsidase Therapy in Patients with Fabry Disease on Renal Replacement Therapy: a Nationwide Study in Italy. Nephrol. Dial. Transplant., 2008, 23 , 1628–1635.

    Pisani A. , 'Agalsidase Therapy in Patients with Fabry Disease on Renal Replacement Therapy: a Nationwide Study in Italy ' (2008 ) 23 Nephrol. Dial. Transplant. : 1628 -1635.

    • Search Google Scholar
  • De Backer, J., Matthys, D., Gillebert, T. C. és mtsai: The use of tissue doppler imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. Eur. J. Echocardiogr., 2005, 6 , 243–250.

    Gillebert T. C. , 'The use of tissue doppler imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies ' (2005 ) 6 Eur. J. Echocardiogr. : 243 -250.

    • Search Google Scholar
  • Kampmann, C., Wiethoff, C. M., Martin, C. és mtsai: Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr., 2002, 91 , 21–27.

    Martin C. , 'Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy ' (2002 ) 91 Acta Paediatr. : 21 -27.

    • Search Google Scholar
  • Hughes, M., Lip, G. Y.: Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost., 2008, 99 , 295–304.

    Lip G. Y. , 'Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data ' (2008 ) 99 Thromb. Haemost. : 295 -304.

    • Search Google Scholar
  • Padanilam, B. J., Prystowsky, E. N.: Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Med. Clin. North Am., 2008, 92 , 217–235.

    Prystowsky E. N. , 'Atrial fibrillation: goals of therapy and management strategies to achieve the goals ' (2008 ) 92 Med. Clin. North Am. : 217 -235.

    • Search Google Scholar
  • Waldo, A. L.: Anticoagulation: stroke prevention in patients with atrial fibrillation. Med. Clin. North Am., 2008, 92 , 143–159.

    Waldo A. L. , 'Anticoagulation: stroke prevention in patients with atrial fibrillation ' (2008 ) 92 Med. Clin. North Am. : 143 -159.

    • Search Google Scholar
  • Strotmann, J., Weidemann, F., Breunig, F. és mtsai: Morbus Fabry of the heart. Why should cardiologists care? Z. Kardiol., 2005, 94 , 557–563.

    Breunig F. , 'Morbus Fabry of the heart. Why should cardiologists care? ' (2005 ) 94 Z. Kardiol. : 557 -563.

    • Search Google Scholar
  • Pieroni, M., Chimenti, C., De Cobelli, F. és mtsai: Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J. Am. Coll. Cardiol., 2006, 47 , 1663–161.

    Cobelli F. , 'Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization ' (2006 ) 47 J. Am. Coll. Cardiol. : 1663 -161.

    • Search Google Scholar
  • Imbriaco, M., Spinelli, L., Cuocolo, A. és mtsai: MRI characterization of myocardial tissue in patients with Fabry’s disease. AJR Am. J. Roentgenol., 2007, 188 , 850–853.

    Cuocolo A. , 'MRI characterization of myocardial tissue in patients with Fabry’s disease ' (2007 ) 188 AJR Am. J. Roentgenol. : 850 -853.

    • Search Google Scholar
  • Sechtem, U., Mahrholdt, H., Vogelsberg, H.: Cardiac magnetic resonance in myocardial disease. Heart, 2007, 93 , 1520–1527.

    Vogelsberg H. , 'Cardiac magnetic resonance in myocardial disease ' (2007 ) 93 Heart : 1520 -1527.

    • Search Google Scholar
  • Moon, J. C., Sheppard, M., Reed, E. és mtsai: The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J. Cardiovasc. Magn. Reson., 2006, 8 , 479–482.

    Reed E. , 'The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease ' (2006 ) 8 J. Cardiovasc. Magn. Reson. : 479 -482.

    • Search Google Scholar
  • Beer, M., Weidemann, F., Breunig, F. és mtsai: Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am. J. Cardiol., 2006, 97 , 1515–1518.

    Breunig F. , 'Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy ' (2006 ) 97 Am. J. Cardiol. : 1515 -1518.

    • Search Google Scholar
  • Horowitz, S. H.: The diagnostic workup of patients with neuropathic pain. Med. Clin. North Am., 2007, 91 , 21–30.

    Horowitz S. H. , 'The diagnostic workup of patients with neuropathic pain ' (2007 ) 91 Med. Clin. North Am. : 21 -30.

    • Search Google Scholar
  • Lacomis, D., Roeske-Anderson, L., Mathie, L.: Neuropathy and Fabry’s disease. Muscle Nerve, 2005, 31 , 102–107.

    Mathie L. , 'Neuropathy and Fabry’s disease ' (2005 ) 31 Muscle Nerve : 102 -107.

  • Gomes, I., Nora, D. B., Becker, J. és mtsai: Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease. J. Neurol. Sci., 2003, 214 , 21–25.

    Becker J. , 'Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease ' (2003 ) 214 J. Neurol. Sci. : 21 -25.

    • Search Google Scholar
  • Ginsberg, L., Manara, R., Valentine, A. R. és mtsai: Magnetic resonance imaging changes in Fabry disease. Acta Paediatr., 2006, 95 , 57–62.

    Valentine A. R. , 'Magnetic resonance imaging changes in Fabry disease ' (2006 ) 95 Acta Paediatr. : 57 -62.

    • Search Google Scholar
  • Lidove, O., Klein, I., Lelievre, J. D. és mtsai: Imaging features of Fabry disease. AJR Am. J. Roentgenol., 2006, 186 , 1184–1191.

    Lelievre J. D. , 'Imaging features of Fabry disease ' (2006 ) 186 AJR Am. J. Roentgenol. : 1184 -1191.

    • Search Google Scholar
  • Moore, D. F., Ye, F., Schiffmann, R. és mtsa: Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am. J. Neuroradiol., 2003, 24 , 1096–1101.

    Schiffmann R. , 'Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease ' (2003 ) 24 AJNR Am. J. Neuroradiol. : 1096 -1101.

    • Search Google Scholar
  • Moore, D. F., Kaneski, C. R., Askari, H. és mtsa: The cerebral vasculopathy of Fabry disease. J. Neurol. Sci., 2007, 257 , 258–263.

    Askari H. , 'The cerebral vasculopathy of Fabry disease ' (2007 ) 257 J. Neurol. Sci. : 258 -263.

    • Search Google Scholar
  • Garzuly, F., Maródi, L., Erdős, M. és mtsai: Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the alpha-galactosidase A gene. Brain, 2005, 128 , 2078–2083.

    Erdős M. , 'Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the alpha-galactosidase A gene ' (2005 ) 128 Brain : 2078 -2083.

    • Search Google Scholar
  • Rolfs, A., Bottcher, T., Zschiesche, M. és mtsai: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet, 2005, 366 , 1794–1796.

    Zschiesche M. , 'Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study ' (2005 ) 366 Lancet : 1794 -1796.

    • Search Google Scholar
  • Mehta, A., Ginsberg, L.: Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr., 2005, 94 , 24–27.; discussion 9–10.

    Ginsberg L. , 'Natural history of the cerebrovascular complications of Fabry disease ' (2005 ) 94 Acta Paediatr. : 24 -27.; discussion 9–10.

    • Search Google Scholar
  • Barbey, F., Brakch, N., Linhart, A. és mtsai: Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr., 2006, 95 , 63–68.

    Linhart A. , 'Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease ' (2006 ) 95 Acta Paediatr. : 63 -68.

    • Search Google Scholar
  • Rincon, F., Sacco, R. L.: Secondary stroke prevention. J. Cardiovasc. Nurs., 2008, 23 , 34–41. Quiz 2-3.

    Sacco R. L. , 'Secondary stroke prevention ' (2008 ) 23 J. Cardiovasc. Nurs. : 34 -41. Quiz 2-3.

    • Search Google Scholar
  • Romero, J. R.: Prevention of ischemic stroke: overview of traditional risk factors. Curr. Drug. Targets, 2007, 8 , 794–801.

    Romero J. R. , 'Prevention of ischemic stroke: overview of traditional risk factors ' (2007 ) 8 Curr. Drug. Targets : 794 -801.

    • Search Google Scholar
  • Goldstein, L. B., Adams, R., Alberts, M. J. és mtsai: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation, 2006, 113 , e873–e923.

    Alberts M. J. , 'Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group ' (2006 ) 113 Circulation : e873 -e923.

    • Search Google Scholar
  • Goldstein, L. B., Adams, R., Alberts, M. J. és mtsai: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37 , 1583–1633.

    Alberts M. J. , 'Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline ' (2006 ) 37 Stroke : 1583 -1633.

    • Search Google Scholar
  • Hegemann, S., Hajioff, D., Conti, G. és mtsai: Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur. J. Clin. Invest., 2006, 36 , 654–662.

    Conti G. , 'Hearing loss in Fabry disease: data from the Fabry Outcome Survey ' (2006 ) 36 Eur. J. Clin. Invest. : 654 -662.

    • Search Google Scholar
  • Hoffmann, B., Keshav, S.: Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr., 2007, 96 , 84–86.

    Keshav S. , 'Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment ' (2007 ) 96 Acta Paediatr. : 84 -86.

    • Search Google Scholar
  • Hoffmann, B., Schwarz, M., Mehta, A. és mtsa: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin. Gastroenterol. Hepatol., 2007, 5 , 1447–1453.

    Mehta A. , 'Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy ' (2007 ) 5 Clin. Gastroenterol. Hepatol. : 1447 -1453.

    • Search Google Scholar
  • Feriozzi, S., Torre, E. S., Ranalli, T. V. és mtsai: A diagnosis of Fabry gastrointestinal disease by chance: a case report. Eur. J. Gastroenterol. Hepatol., 2007, 19 , 163–165.

    Ranalli T. V. , 'A diagnosis of Fabry gastrointestinal disease by chance: a case report ' (2007 ) 19 Eur. J. Gastroenterol. Hepatol. : 163 -165.

    • Search Google Scholar
  • Magage, S., Lubanda, J. C., Susa, Z. és mtsai: Natural history of the respiratory involvement in Anderson-Fabry disease. J. Inherit. Metab. Dis., 2007, 30 , 790–799.

    Susa Z. , 'Natural history of the respiratory involvement in Anderson-Fabry disease ' (2007 ) 30 J. Inherit. Metab. Dis. : 790 -799.

    • Search Google Scholar
  • Mersebach, H., Johansson, J. O., Rasmussen, A. K. és mtsai: Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet. Med., 2007, 9 , 812–818.

    Rasmussen A. K. , 'Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density ' (2007 ) 9 Genet. Med. : 812 -818.

    • Search Google Scholar